Key statistics dashboard for None (BLRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Stock Data
| Price | $2.48 |
| Market Cap | $11M |
| Enterprise Value | $14.5M |
| Beta | 0.48 |
Valuation Multiples
| P/E Ratio | -1.38 |
| Price / Book | 0.83 |
| P/S | 7.97 |
| EV/EBITDA | -1.28 |
| EV/Sales | 10.36 |
| EV/FCF | -1.32 |
| P/FCF | -1.02 |
| Earnings Yield | -70.54% |
| FCF Yield | -98.24% |
Profitability
| Gross Margin | 69.79% |
| EBIT Margin | -832.92% |
| EBITDA Margin | -806.61% |
| Operating Margin | -874.34% |
| Net Margin | -574.17% |
| Return on Equity | -47.22% |
| Return on Assets | -24.17% |
| Return on Invested Capital | -50.11% |
| Return on Capital Employed | -62.23% |
Financial Health
| Current Ratio | 1.20 |
| Quick Ratio | 1.04 |
| Cash Ratio | 0.34 |
| Debt / Equity | 0.58 |
| Debt / Assets | 23.88% |
| Net Debt / EBITDA | -0.30 |
| Interest Coverage | -11.65 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 0.09 |
| Cash per share | 0.07 |
| FCF per share | -0.06 |
| Tangible Book Value per share | 0.00 |
| Dividend per share | 0.00 |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · GOVX · ICU
More sections of BLRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks